Research Article
Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
| Characteristics | Number of patients (n = 167), no. (%) |
| Age | Mean | 66.5 | Median | 68.0 | Range | 18–95 |
| Sex | Male | 105 (62.9) | Female | 62 (37.1) |
| Performance status (ECOG score) | 0 | 143 (85.6) | 1 | 16 (9.6) | 2 | 6 (3.6) | 3 | 1 (0.6) | 4 | 1 (0.6) |
| Subtype | Cutaneous | 122 (73.1) | Desmoplastic | 1 (0.6) | Mucosal | 7 (4.2) | Nevoid melanoma | 1 (0.6) | Nodular | 28 (16.8) | Pigment synthesizing melanoma | 1 (0.6) | Spindle cell malignant melanoma | 2 (1.2) | Not known | 5 (3.0) |
| BRAF V600 mutation | No | 105 (62.9) | Not known | 8 (4.8) | Yes | 54 (32.3) |
| Sites of metastasis | Bone | 49 (29.3) | Central nervous system | 56 (33.5) | Lymph nodes | 143 (85.6) | Liver | 73 (43.7) | Lung | 119 (71.3) | Soft tissue and others | 108 (64.7) |
| ICI treatment received | Ipilimumab + nivolumab | 6 (3.6) | Nivolumab | 19 (11.4) | Pembrolizumab | 142 (85.0) |
| Immune-related adverse events | Gastrointestinal | 33 (9.8) | Pneumonitis | 16 (9.6) | Thyroid | 14 (8.4) | Diabetes | 2 (1.2) | Adrenal insufficiency | 5 (3.0) | Hypophysitis | 2 (1.2) | Neurologic | 12 (7.2) | Hematologic | 1 (0.6) | Renal | 9 (5.4) | Musculoskeletal | 11 (6.6) | Skin | 35 (21.0) |
| Cause of ICI discontinuation (if discontinued) | Progressive disease | 72 (43.1) | Toxicity | 37 (22.2) | Best response | 24 (14.4) | Ongoing | 15 (9.0) | Death | 9 (5.4) | Not known | 8 (4.8) | Others | 2 (1.2) |
|
|